<SEC-DOCUMENT>0001206774-14-000309.txt : 20140127
<SEC-HEADER>0001206774-14-000309.hdr.sgml : 20140127
<ACCEPTANCE-DATETIME>20140127063022
ACCESSION NUMBER:		0001206774-14-000309
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20140122
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20140127
DATE AS OF CHANGE:		20140127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		14547376

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>January
22, 2014</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION</FONT></B><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant as specified in its
charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD noWrap align=left width="33%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A <BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General
Instruction A.2. below): </FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Wingdings size=2>&#168;</FONT></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 under the Securities
      Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Arial size=2><FONT face=Wingdings>&#168;</FONT></FONT>&nbsp; </TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)</FONT>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Arial size=2><FONT face=Wingdings>&#168;</FONT><FONT face="Times New Roman" size=3>&nbsp;
      </FONT></FONT></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 <FONT face="Times New Roman" size=2>CFR
      240.14d-2(b))</FONT></FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Arial size=2><FONT face=Wingdings>&#168;</FONT><FONT face="Times New Roman" size=3>&nbsp;
      </FONT></FONT></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 <FONT face="Times New Roman" size=2>CFR
      240.13e-4(c))</FONT></FONT>&nbsp; </TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 7.01 Regulation FD Disclosure.
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In November 2012, Dr. Ayalew Tefferi
(the &#147;investigator&#148;), of Mayo Clinic, initiated an investigator-sponsored
clinical trial to evaluate imetelstat in patients with myelofibrosis and other
myeloid malignancies (the &#147;Myelofibrosis IST&#148;). Mayo Clinic has informed Geron
Corporation (the &#147;Company&#148; or &#147;Geron&#148;) that effective January 22, 2014, the
Myelofibrosis IST has been closed to new patient enrollment, and that the
remaining patients in the study will continue to receive imetelstat treatment
and be followed under the Myelofibrosis IST protocol. The Company believes that
approximately 79 patients have been enrolled in the Myelofibrosis IST, including
nine patients with blast-phase myelofibrosis and nine patients with refractory
anemia with ringed sideroblasts (&#147;RARS&#148;), a subpopulation of myelodysplastic
syndromes, and that approximately 20 patients have discontinued from the study
since its inception. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In December 2013 at the American Society of Hematology Annual Meeting, the investigator presented preliminary data from the first two cohorts of patients in the Myelofibrosis IST, including preliminary efficacy data for 22 patients and preliminary safety data for 33 patients. Based on this preliminary efficacy and safety data, the Company plans to
initiate a Geron-sponsored, multi-center, Phase 2 clinical trial of imetelstat
in patients with myelofibrosis in the first half of 2014. The Company also
believes that the total accrued patients in the Myelofibrosis IST will be
adequate for gathering additional and updated safety and efficacy data to
support the imetelstat development program.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company expects that the
investigator will present at a future medical conference additional and updated
safety and efficacy data, including longer-term durability, for those patients
previously reported and for additional remaining patients in the Myelofibrosis
IST.</FONT><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The information contained in this Item 7.01 to this Current Report shall be deemed to be &ldquo;furnished&rdquo; and shall not be
deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or
otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). The information contained in this Item 7.01 to this Current Report shall not be incorporated by reference into any
filing with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act made by the Company,
whether made before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Use of Forward-Looking Statements
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except for statements of historical
fact, this Current Report on Form 8-K contains forward-looking statements made
pursuant to the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements regarding: the
remaining patients in </FONT><FONT face="Times New Roman" size=2>the Myelofibrosis
IST</FONT><FONT face="Times New Roman" size=2> continuing to </FONT><FONT face="Times New Roman" size=2>receive imetelstat treatment</FONT><FONT face="Times New Roman" size=2>; the
Company&#146;s planned Phase 2 clinical trial of imetelstat and the timing thereof;
and other statements that are not historical facts. These forward-looking
statements are generally identified by words such as &#147;expect,&#148; &#147;plan,&#148; &#147;will,&#148;
and other similar expressions. In addition, any statements that refer to
expectations, projections, or other characterizations of future events or
circumstances are forward-looking statements. These statements involve risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. These risks and uncertainties include, without
limitation, risks and uncertainties regarding: that </FONT><FONT face="Times New Roman" size=2>Geron</FONT><FONT face="Times New Roman" size=2> could be unable to initiate the
planned </FONT><FONT face="Times New Roman" size=2>Phase 2 clinical trial</FONT><FONT face="Times New Roman" size=2> of imetelstat in a timely manner or at all; Geron&#146;s reliance
on the conduct of and data from the Myelofibrosis IST; Geron&#146;s reliance on the
investigator to continue to treat and follow patients in</FONT><FONT face="Times New Roman" size=2> the Myelofibrosis IST</FONT><FONT face="Times New Roman" size=2>; the fact that
preliminary efficacy and safety data that the Company has reported from the
</FONT><FONT face="Times New Roman" size=2>Myelofibrosis IST</FONT><FONT face="Times New Roman" size=2>
may be materially different from the final data generated in the trial; that one
or more of the efficacy or safety outcomes in the Myelofibrosis IST</FONT><FONT face="Times New Roman" size=2> may materially change as
patient treatment continues and additional and updated patient data becomes
available; that adverse safety events could cause the benefit-risk profile for
imetelstat to become unacceptable; and those other risks and uncertainties
inherent in the development of potential therapeutic products such as successful
company-sponsored clinical trial results; technical, scientific and regulatory
challenges; sufficient capital resources; limitations on Geron&#146;s freedom to
operate arising from intellectual property of others; and challenges or
enforcement of Geron&#146;s intellectual property rights. More detailed additional information and factors that
could cause actual results to differ materially from those in the
forward-looking statements is contained in Geron&#146;s periodic reports filed with
the Securities and Exchange Commission primarily under the heading &#147;Risk
Factors,&#148; including in Geron&#146;s quarterly report on Form 10-Q for the quarter
ended September 30, 2013. Undue reliance should not be placed on Geron&#146;s
forward-looking statements. Except as required by law, Geron disclaims any
obligation to update these forward-looking statements to reflect future
information, events or circumstances. </FONT></P>


<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="74%"></TD>
    <TD noWrap align=left width="26%" colSpan=2><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%"><FONT face="Times New Roman" size=2>Date: January 27, 2014</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="25%"><FONT face="Times New Roman" size=2>/s/ Stephen N.
      Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="25%"><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="25%"><FONT face="Times New Roman" size=2>Executive Vice President, General</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="25%"><FONT face="Times New Roman" size=2>Counsel and Corporate Secretary</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
